• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Teva to Acquire Allergan Generics, Withdraws from Mylan Deal


July 27, 2015.

Teva Pharmaceutical Industries Ltd. (Petach Tikva, Israel) has announced that it has signed a definitive agreement to acquire the generics business of Allergan (Dublin, Ireland) in a transaction valued at $40.5 billion.   Upon closing, Allergan will receive $33.75 billion in cash and shares of Teva valued today at $6.75 billion.     The Israeli firm simultaneously announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary shares of Mylan N.V. (Amsterdam, The Netherlands).   http://www.tevapharm.com/news_media/

Recent Videos
Related Content